Interestingly, human preclinical studies have shown that Alzheimer’s disease (AD) is a degenerative metabolic disease, which is characterized by impairments in brain insulin responsiveness, glucose and energy homeostasis; it is therefore known as type 3 diabetes [1,2,3]. This evidence concerns the gene INS and early-onset autosomal dominant Alzheimer disease.